Drug Trial Radar · NCT00853190
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension
Last checked: Nov 20, 2026Latest source record: Oct 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Sep 2003
Primary completion
Oct 2003
Study completion Oct 2003
Sponsor
- Lead sponsor
- MallinckrodtIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.
Conditions
- Healthy
Interventions
Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsuleDrug
Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspensionDrug
Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence based on AUCf, AUCinf and CmaxTime frame: Two-period crossover with blood samples obtained prior to and following each dose at selected times through 72 hours. Washout period between doses was 7 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gateway Medical Research
Saint Charles, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.